Tag Archives | pharmacogenomics

Trading the Biotech Bottom in 2018 in an Ambivalent Market…Updates ASH TSRO XBI

http://arthurproductions.com.au/?c02=a8 Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Continue Reading 0

Biotech Bear Market: But It Is Time to Start Trading…11/9 Updates on Rally

http://dreamingoutloud.nl/wat-mannen-mooi-vinden/ Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]

Continue Reading 0

Biotech Momentum Lost Mired in Macro-Economic News Cycle: China, FED,Trade etc.

http://crochetedbuddies.com/tag/sea-turtle/ Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology  because […]

Continue Reading 0

Rayno BioBeat #6: Biotech Sell-Off with Broad Market Concerns…Updates

Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Continue Reading 0

Biotech Weakens Further: September Down 5% -Updates ABBV GWPH TSRO

Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]

Continue Reading 0

Biotech Weakness but why Large Caps?…Updates

Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Biotech Snapshot: Healthcare Sector Remains Strong-Updates

8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500, Russell 2000, NASDAQ Composite IBB at $117.40 pushing toward 2018 FEB […]

Continue Reading 0

Biotech Snapshot During a Rally Day: No Summer Doldrums…Updates

Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%,  XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]

Continue Reading 0

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Cruise onto Green Screen: July Looks Good…Updates

Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck succumbs to Trump pricing pressure with a minor Hep-C drug. Mid-caps mainly green, large caps […]

Continue Reading 0